PT94789A - Metodo para inibicao da replicacao viral em celulas de mamifero usando conjugados da proteina antiviral da erva-dos-cancros-anticorpos monoclonais - Google Patents

Metodo para inibicao da replicacao viral em celulas de mamifero usando conjugados da proteina antiviral da erva-dos-cancros-anticorpos monoclonais

Info

Publication number
PT94789A
PT94789A PT94789A PT9478990A PT94789A PT 94789 A PT94789 A PT 94789A PT 94789 A PT94789 A PT 94789A PT 9478990 A PT9478990 A PT 9478990A PT 94789 A PT94789 A PT 94789A
Authority
PT
Portugal
Prior art keywords
mamiferous
dos
herb
antibodies
cells
Prior art date
Application number
PT94789A
Other languages
English (en)
Other versions
PT94789B (pt
Inventor
Fatih M Uckun
Joyce Mintzer Zarling
Original Assignee
Univ Minnesota
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Oncogen filed Critical Univ Minnesota
Publication of PT94789A publication Critical patent/PT94789A/pt
Publication of PT94789B publication Critical patent/PT94789B/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT94789A 1989-07-25 1990-07-23 Metodo para inibicao da replicacao viral em celulas de mamifero usando conjugados da proteina antiviral da erva-dos-cancros-anticorpos monoclonais PT94789B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30

Publications (2)

Publication Number Publication Date
PT94789A true PT94789A (pt) 1991-03-20
PT94789B PT94789B (pt) 1997-04-30

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94789A PT94789B (pt) 1989-07-25 1990-07-23 Metodo para inibicao da replicacao viral em celulas de mamifero usando conjugados da proteina antiviral da erva-dos-cancros-anticorpos monoclonais

Country Status (17)

Country Link
EP (1) EP0441917B1 (pt)
JP (1) JP3109678B2 (pt)
KR (1) KR920700698A (pt)
AT (1) ATE137410T1 (pt)
AU (1) AU631674B2 (pt)
CA (1) CA2037900C (pt)
DE (1) DE69026812T2 (pt)
DK (1) DK0441917T3 (pt)
ES (1) ES2087158T3 (pt)
FI (1) FI911447A0 (pt)
GR (1) GR1002180B (pt)
IE (1) IE74143B1 (pt)
IL (1) IL95134A (pt)
NO (1) NO911174L (pt)
NZ (1) NZ234607A (pt)
PT (1) PT94789B (pt)
WO (1) WO1991001145A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (pt) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 glp-1 유도체

Also Published As

Publication number Publication date
DK0441917T3 (da) 1996-09-16
IL95134A (en) 1996-01-31
IE74143B1 (en) 1997-07-02
EP0441917A1 (en) 1991-08-21
DE69026812T2 (de) 1996-11-28
NO911174D0 (no) 1991-03-22
ES2087158T3 (es) 1996-07-16
FI911447A0 (fi) 1991-03-25
NZ234607A (en) 1992-10-28
WO1991001145A1 (en) 1991-02-07
CA2037900C (en) 1999-11-16
NO911174L (no) 1991-05-24
PT94789B (pt) 1997-04-30
GR1002180B (en) 1996-03-11
AU631674B2 (en) 1992-12-03
AU6140590A (en) 1991-02-22
CA2037900A1 (en) 1991-01-26
DE69026812D1 (de) 1996-06-05
IL95134A0 (en) 1991-06-10
IE902593A1 (en) 1991-02-27
GR900100550A (el) 1991-12-10
JPH04502625A (ja) 1992-05-14
ATE137410T1 (de) 1996-05-15
KR920700698A (ko) 1992-08-10
JP3109678B2 (ja) 2000-11-20
EP0441917B1 (en) 1996-05-01

Similar Documents

Publication Publication Date Title
IT8921515A0 (it) Procedimento per la preparazione di estratti ad alto contenuto in antocianosidi.
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
ES2067604T3 (es) Anticuerpos frente a proteina que se une a tnf i y a sus fragmentos f(ab).
DK156688D0 (da) Praeparat til behandling af virusinfektioner
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
DK228486D0 (da) Retrovirale polypeptider med tilknytning til human celletransformation
MX9847A (es) Conjugados de inmunoglobulina y procedimiento para su preparacion.
MX173892B (es) Procedimiento y dispositivo para obtener hojas de vidrio abombadas
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
NO881077D0 (no) Kjemo-radio-immuno-konjugater.
NO910003L (no) Vitamin e-derivater og fremgangsmaate for deres fremstilling.
CY1108288T1 (el) Αντισωματα για το αντιγονο κυτταρων langerhans θηλαστικων και χρησεις τους
PT94789A (pt) Metodo para inibicao da replicacao viral em celulas de mamifero usando conjugados da proteina antiviral da erva-dos-cancros-anticorpos monoclonais
FR2637897B1 (fr) Dosages immunologiques de l'azt, derives et conjugues et anticorps
DE69231495D1 (de) Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen
DE69717568D1 (de) S-(+)-Adenosylmethionine und 3'-Azido-2',3'-Dideoxy-Nukleosid-Komplexe als potente Inhibitoren von HIV-Replikation
DK314886D0 (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
ES2019859A4 (es) Dispositivo para soportar y transportar laminas de vidrio.
ATE51894T1 (de) Spezifische mycoplasma-membran-antigene und antik¯rper sowie deren klinische verwendungen.
DE68912772D1 (de) Monoklonaler antikörper gegen entero-viren.
FI904268A0 (fi) Anordning foer arbeten i t.ex. roerledningar.
ES1015772Y (es) Perfeccionamientos en piezas para union de colgantes.
ES1008673Y (es) Triptico plegable para informacion general dotado de fichas complementarias.
SE9002479D0 (sv) Antibody conjugates
ES1005330Y (es) Pieza para sujecion de colgantes de lamparas y similares.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19901024

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20040722